Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTLE: Anti-CD19 CAR T in Autoimmune Diseases
NCT06347718Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of zorpocabtagene autoleucel in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis (PM), sponsored by Miltenyi Biomedicine GmbH. Started Jul 2023; status: recruiting.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT06347718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06347718.